Note 22 - Subsequent Events

12 Months Ended

Dec. 31, 2020

Notes to Financial Statements

Subsequent Events [Text Block]

22.          Subsequent Events

Financings

On January 12, 2021, the Company sold, in a registered direct offering, 25,000,000 shares of common stock at a purchase price per share of $1.25 for aggregate gross proceeds of $31.25 million, and net proceeds of $28.8 million.

On January 29, 2021, the Company completed an underwritten public offering of 26,725,832 shares of its common stock, including the underwriter’s full exercise of an over-allotment option on February 1, 2021, at the public offering price of $3.00 per share, generating net proceeds of approximately $73.5 million.

As of the date of this filing Series B, C and D warrants have been exercised during 2021 for aggregate proceeds to the Company of $30.4 million.

From January 1, 2021 through to the date of this filing the following table summarizes the total sales under the 2020 ATM Offering (in thousands except for per share amounts). The 2020 ATM Offering was terminated on January 26, 2021.

Total shares of common stock sold		19,120
Average price per share	$	1.47
Gross proceeds	$	28,100
Commissions earned by Cantor	$	843
Net Proceeds	$	27,257

Name change

Effective on February 23, 2021, the Company changed its name from TransEnterix, Inc. to Asensus Surgical, Inc. On March 5, 2021, the ticker symbol of the Company’s common stock on the NYSE American changed from “TRXC” to “ASXC.”